Lantheus (NASDAQ:LNTH) Lowered to Buy Rating by Wall Street Zen

Lantheus (NASDAQ:LNTH) was downgraded by research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Sunday.

Several other equities analysts have also commented on LNTH. Citizens Jmp raised their target price on shares of Lantheus from $73.00 to $78.00 and gave the company a “market outperform” rating in a report on Tuesday, February 24th. Mizuho upped their price target on shares of Lantheus from $72.00 to $85.00 and gave the stock an “outperform” rating in a report on Friday, February 27th. Citigroup reiterated an “outperform” rating on shares of Lantheus in a research report on Tuesday, February 24th. William Blair raised shares of Lantheus from a “market perform” rating to an “outperform” rating in a research note on Thursday, February 26th. Finally, Truist Financial boosted their price objective on shares of Lantheus from $82.00 to $89.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Seven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $82.17.

Lantheus Stock Down 1.2%

Shares of NASDAQ LNTH opened at $79.49 on Friday. The company has a market cap of $5.17 billion, a price-to-earnings ratio of 23.59 and a beta of -0.11. Lantheus has a 12-month low of $47.25 and a 12-month high of $108.91. The company has a quick ratio of 2.51, a current ratio of 2.70 and a debt-to-equity ratio of 0.52. The firm’s 50-day simple moving average is $70.53 and its 200 day simple moving average is $61.79.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 EPS for the quarter, topping analysts’ consensus estimates of $1.17 by $0.50. The company had revenue of $406.79 million for the quarter, compared to analysts’ expectations of $367.03 million. Lantheus had a return on equity of 30.77% and a net margin of 15.15%.Lantheus’s revenue was up 4.0% on a year-over-year basis. During the same quarter last year, the business earned $1.59 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, research analysts expect that Lantheus will post 6.01 earnings per share for the current fiscal year.

Institutional Trading of Lantheus

Institutional investors have recently modified their holdings of the business. Hantz Financial Services Inc. raised its position in Lantheus by 412.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 396 shares during the last quarter. Elevation Point Wealth Partners LLC acquired a new stake in shares of Lantheus in the second quarter valued at about $26,000. First Horizon Corp acquired a new stake in shares of Lantheus in the third quarter valued at about $26,000. Smartleaf Asset Management LLC raised its position in shares of Lantheus by 63.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 197 shares during the last quarter. Finally, Parallel Advisors LLC raised its position in shares of Lantheus by 122.6% during the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 298 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.